MedTrace Logo

Effect of ANKASCIN 568-P Products on Decreasing HbA1c and Regulating Blood Glucose

NCT05737342 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-08-28

No results posted yet for this study

Summary

This study is a randomized, double-blind, placebo-controlled, parallel-controlled trial (24 weeks in total), divided into three periods (screening, treatment, and discontinuation follow-up)

Conditions

  • High Blood Sugar
  • Metabolic Syndrome

Interventions

DIETARY_SUPPLEMENT

ANKASCIN 568-P Red yeast rice capsules

Product ingredients: ANKASCIN 568-P red yeast rice product 440 mg,microcrystalline ,cellulose,Maltodextrin; capsule shell composition: HPMC (hydroxypropyl methylcellulose), purified water, titanium dioxide, gellan gum.

DIETARY_SUPPLEMENT

Placebo Capsules

Maltodextrin was used as a placebo

Sponsors & Collaborators

  • SunWay Biotech Co., LTD.

    lead INDUSTRY

Principal Investigators

  • WEN-HUI FANG, Ph. D. · Chief of Family medicine department

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-01
Primary Completion
2025-10-31
Completion
2025-10-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05737342 on ClinicalTrials.gov